

**TELECOPIER MESSAGE
HOWSON AND HOWSON
321 Norristown Road
P.O. Box 457
Spring House, PA 19477**

TO: Ms. Deborah Dotson
Group Art Unit: 1631

FROM: Tracy U. Palovich, Ph.D.

DATE: January 24, 2003

REFERENCE: U.S. Patent Application No. 09/700,329 for
"Prevention and Treatment of Hypergastrinemia"
(Philip C. Gevas, et al.) Our Ref: ACG2AUSA

NUMBER OF PAGES (including cover sheet): 23

FACSIMILE NUMBER OF RECIPIENT: 703/746-8698

TELEPHONE: (215) 540-9200
FACSIMILE: (215) 540-5818
E-MAIL: howson2@aol.com

The information contained in this fax message (including the accompanying pages, if any) is intended only for the personal and confidential use of the designated recipient(s). This may be privileged attorney-client communication. If you are not a designated recipient or an agent responsible for delivery of this message, you have received this document in error, and any review, dissemination, distribution, use or copying is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone or return fax, and return the original by mail. Thank you.

HOWSON AND HOWSON

ATTORNEYS AT LAW

Established 1853 Philadelphia

SPRING HOUSE CORPORATE CENTER
321 NORRISTOWN ROAD
P.O. BOX 457
SPRING HOUSE, PA 19477

PATENTS TRADEMARKS COPYRIGHTS

TELEPHONE (215) 540-9200

FACSIMILE (215) 540-5818

Counsel
WILSON OBERDORFER
CHARLES M. ALLEN

STANLEY B. KITA
GEORGE ANTHONY SMITH, JR.
MARY ELIZABETH BAK
CATHY A. KODROFF
WILLIAM BAK
HENRY HANSEN

Reg. Patent Agents
TRACY U. PALOVICH, Ph.D.
IRENE J. FRANGOS

January 24, 2003

Deborah Dotson
US Patent and Trademark Office
Washington, DC 20231

Re: US Patent Application No. 09/700,329 for "*Prevention and Treatment of Hypergastrinemia*", (Geyas et al.) Our Ref: ACG2AUSA

Dear Ms. Dotson:

Pursuant to our telephone conference of January 22, 2003, enclosed please find a copy of a Response to a *Notice to Comply with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure* dated March 28, 2002. We did not enclose a CRF copy of the sequence listing since the sequence department of the US Patent and Trademark Office verified on October 11, 2002 that the same was received and found acceptable.

Please note that this Response, with enclosures, was timely hand-delivered to the US Patent and Trademark Office on April 25, 2002. We have enclosed a copy of the stamped postcard indicating receipt of the same.

We request that the enclosed Response be entered so that the application can be forwarded for examination in due course.

Your assistance is greatly appreciated.

Very truly yours,

HOWSON AND HOWSON

Tracy U. Palovich, Ph.D.
Patent Agent

TUP/bh
Enclosures

PATENT Serial No. 09/100,329 Doc. No. ACG2AUS1 Atty/Sec MEB/bh Date 4-25-02
Inventor P. G. UAS Client AFCG
Title PREVENTION AND TREATMENT OF HYPERGASTRINEMA
The following has been received in the U.S. Patent and Trademark Office on the date stamped hereon:
 pp. Spec., Claims, Abstract pp. Amendment: OA dtd 3-25-02
 pp. Declaration/Power of Attorney pp. Response: OA dtd 3-25-02
 pp. Verified Statement (Small Entry) pp. Transmittal Letter
 shts. Informal Drawings Issue Fee
 shts. Formal Drawings Notice of Appeal & Fee
 pp. Assignment 62:2 Check # for \$
 pp. Preliminary Amendment 11-14-00 X 3P. STATEMENT TO SUPPORT
 pp. Extension of Time S2 X 3P. SEQUENCE LISTING
 pp. Information Disclosure Statement X 3P. COPY OF 35 U.S.C. OFFICE ACTION
with PTO-1449 and 02 references X 1 DISK - C FR 4 SEQUENCE LISTING

The Patent and Trademark Office is respectfully requested to place its stamp on this postal card and place it in the outgoing mail.

1P-E b:TA-Copy of Post Card 11-14-00 Respectfully,
 X3P-Exhibit B Copy of Seq. Listing HOWSON AND HOWSON
 X8P-Exhibit C Copy of Second PAEL MEB
Amendment

4/13-H



00270

PATENT TRADEMARK OFFICE



ACG2AUSA

H16/c
PD
1-29-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1631
P. Gevas et al.)
Appln. No. 09/700,329) Examiner: M. Borin
Filed: February 28, 2001)
For: PREVENTION AND TREATMENT OF) April 25, 2002
HYPERGASTRINEMIA)
)

BOX SEQUENCE
Assistant Commissioner for Patents
Washington, DC 20231

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE**

Sir:

In a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", dated March 28, 2002, Applicant was informed that the above-identified application failed to comply with the requirements of 37 CFR § 1.821-1.825. Specifically, Applicant was informed that:

- (i) The application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR § 1.821(c);
- (ii) A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR § 1.821(e). A paper copy is in the file but is not in accordance with new Sequence Listing Rules; and
- (iii) Applicant is also requested to provide SEQ ID numbers for peptide sequences in the specification and claims.

In response to that Notice, Applicant asserts that pursuant to 37 CFR § 1.821-1.825, a paper copy of the "Sequence Listing", a computer readable form (CRF) of the "Sequence Listing", a Statement to Support Filing and Submission, and an Amendment inserting the Sequence ID numbers were originally filed with the application. As support, Applicant encloses herewith as Exhibits A-C, a copy of the stamped postcard indicating receipt by the US Patent and Trademark Office of the above-noted items, the originally filed paper copy of the "Sequence Listing", and the Preliminary Amendment inserting the sequence ID numbers into the originally filed application. Further, Applicant asserts that the paper copy filed with the application and enclosed herewith as Exhibit B did conform with the new Sequence Listing rules.

However, in an effort to expedite examination of this application and in response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" which was dated March 28, 2002, to which a response is due by April 28, 2002, enclosed herewith are:

- Amendment under 37 CFR § 1.825;
- Statement to Support Filing and Submission in accordance with 37 CFR §§ 1.821 through 1.825;
- Original pages of the Sequence Listing;
- Substitute copy of the pages of the Sequence Listing;
- Original computer readable form of the Sequence Listing;
- Substitute copy of the computer readable form of the Sequence Listing;
- Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- Petition for a _____ month Extension of Time to Reply;
- OTHER:

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for the Applicant

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9206
Telefacsimile: (215) 540-5818